SIRT1 and cancer: Future research should prioritize the development of cancer-selective SIRT1 inhibitors, the integration of biomarker-driven clinical trial designs, and exploration of rational combination strategies with chemotherapy, immunotherapy, or metabolic modulators [48,133].